ONCOBIOME, 1st consortium about microbiome & cancer, led by Gustave Roussy
Gustave Roussy, leading European Cancer Centre, is collaborating with 16 international partners in the Oncobiome consortium. The objective of the programme is to determine the relationship between intestinal microbial signatures (GOMS) and the incidence, prognosis and resistance to treatment (and toxicity of this) in cancers of breast, colon, lung...
Gustave Roussy, leading centre of immunotherapy in Europe
Immunotherapy boosts the immune system to fight cancer cells. Gustave Roussy is a pionner in immunotherapy and the largest tratment facility in Europe. Between 2013 and 2018, 241 immunotherapy-based clinical trials were implemented at the Insitute and 3,317 patients have been treated with immunotherapy.
By their participation in the initial...
Precision drug to stimulate immune system against some cancers
Gustave Roussy's researchers found an unkown ability to PARP inihibitors - a precision cancer drug used against breast and ovarian cancer - to stimulate the immune system. This study suggests to developp new combinaisons of treatments with immunotherapy.